Recommended Intensive Insulin Therapy Regimen for Type 1 Diabetes
Adults with type 1 diabetes should be treated with either continuous subcutaneous insulin infusion (CSII/insulin pump) or multiple daily injections (MDI) consisting of basal insulin plus prandial insulin at each meal, using insulin analogs rather than human insulins. 1
Core Insulin Regimen Components
The intensive insulin therapy regimen consists of three essential elements 1, 2:
- Basal insulin: Long-acting insulin analogs (glargine, detemir, degludec) or continuous rapid-acting insulin via pump
- Prandial/bolus insulin: Rapid-acting analogs (aspart, lispro, glulisine) or inhaled insulin given with each meal
- Correction insulin: Additional rapid-acting insulin to correct elevated blood glucose levels
Why Insulin Analogs Over Human Insulin
Insulin analogs are strongly preferred over injectable human insulins (NPH, regular) because they reduce hypoglycemia risk, minimize weight gain, and achieve lower A1C levels. 1, 2 The landmark DCCT trial demonstrated that intensive therapy reduced microvascular complications by 50% over 6 years, but used human insulins and resulted in severe hypoglycemia rates of 62 episodes per 100 person-years. Modern analog insulins have significantly improved this safety profile 1, 2.
Technology Integration (Critical for Optimal Outcomes)
The 2025 ADA guidelines represent a significant shift in technology recommendations:
- Automated insulin delivery systems should be offered to ALL adults with type 1 diabetes 1 (upgraded from "should be considered" in 2024 2)
- Early continuous glucose monitoring (CGM) is recommended to improve glycemic outcomes, quality of life, and minimize hypoglycemia 1, 2
This represents the current standard of care—technology is no longer optional but integral to optimal management.
Patient Education Requirements
All patients must receive structured education on 1, 2:
- Carbohydrate counting to match insulin doses to meals
- Fat and protein intake adjustment (these also affect postprandial glucose)
- Correction dosing based on current glucose and trends
- Sick-day management protocols
- Physical activity adjustments to prevent hypoglycemia
This education is not supplementary—it's essential for the regimen to work safely and effectively.
Choosing Between MDI and Insulin Pump
While both are acceptable, automated insulin delivery systems (hybrid closed-loop pumps) should be the first-line offer given the 2025 guideline upgrade 1. However, MDI remains appropriate when:
- Patient preference favors injections
- Cost/insurance barriers exist
- Patient is unwilling or unable to manage pump technology
The key is that either approach must use analog insulins in a basal-bolus framework 1, 2.
Monitoring and Adjustment Schedule
Insulin regimens must be reassessed every 3-6 months and adjusted based on 1, 2:
- A1C trends
- Hypoglycemia frequency and severity
- CGM data patterns (time in range, glycemic variability)
- Changes in lifestyle, weight, or concurrent illness
- Insulin-taking behavior and adherence
Common Pitfalls to Avoid
- Using human insulins when analogs are accessible—this unnecessarily increases hypoglycemia risk 1, 2
- Delaying CGM initiation—early use is now explicitly recommended 1
- Not offering automated insulin delivery—this is now a "should offer" recommendation, not optional 1
- Inadequate patient education—the regimen fails without proper training on dose adjustment 1, 2
- Fixed insulin doses—doses must be dynamic and adjusted for food, activity, and glucose trends 1
Evidence Strength
The recommendations are based on Level A evidence from the 2025 ADA Standards of Care 1, representing the highest quality guideline from the most prestigious diabetes organization. The foundational DCCT trial demonstrated 50% reduction in microvascular complications with intensive therapy, with benefits persisting 20 years after the study ended 1, 2. Modern analog insulins and technology have made this approach safer and more effective than when originally studied.